Stocks and Investing
Stocks and Investing
Tue, July 18, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, July 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Yatin Suneja Downgraded (BTAI) to Hold on, Jul 17th, 2023
Yatin Suneja of Guggenheim, Downgraded "BioXcel Therapeutics, Inc." (BTAI) to Hold on, Jul 17th, 2023.
Yatin has made no other calls on BTAI in the last 4 months.
There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 1 agrees with Yatin's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $25 on, Friday, May 26th, 2023
These are the ratings of the 2 analyists that currently disagree with Yatin
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $60 on, Monday, July 3rd, 2023
- Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $40 on, Friday, June 30th, 2023
Contributing Sources